Zoetis Inc. $ZTS Stock Holdings Trimmed by Meiji Yasuda Life Insurance Co

Meiji Yasuda Life Insurance Co reduced its position in Zoetis Inc. (NYSE:ZTS) by 0.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,843 shares of the company’s stock after selling 87 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in Zoetis were worth $7,548,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Nuveen LLC acquired a new stake in Zoetis in the first quarter worth approximately $616,375,000. Sarasin & Partners LLP acquired a new stake in shares of Zoetis during the 1st quarter valued at $339,111,000. Mackenzie Financial Corp lifted its position in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after acquiring an additional 1,782,110 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company’s stock valued at $289,666,000 after acquiring an additional 1,747,423 shares during the last quarter. Finally, Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.0%

NYSE ZTS opened at $153.15 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a 50-day simple moving average of $153.16 and a 200 day simple moving average of $157.73. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The stock has a market cap of $67.87 billion, a PE ratio of 26.36, a PEG ratio of 2.46 and a beta of 0.88.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on ZTS. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.